226,999 Shares in Privia Health Group, Inc. $PRVA Bought by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. bought a new position in shares of Privia Health Group, Inc. (NASDAQ:PRVA) in the 2nd quarter, Holdings Channel.com reports. The fund bought 226,999 shares of the company’s stock, valued at approximately $5,841,000.

Other large investors also recently bought and sold shares of the company. ArrowMark Colorado Holdings LLC boosted its stake in shares of Privia Health Group by 139.4% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 841,266 shares of the company’s stock valued at $19,946,000 after buying an additional 489,866 shares during the period. Freestone Grove Partners LP increased its stake in shares of Privia Health Group by 40.6% during the fourth quarter. Freestone Grove Partners LP now owns 1,213,342 shares of the company’s stock worth $28,768,000 after buying an additional 350,194 shares during the period. Renaissance Group LLC purchased a new stake in shares of Privia Health Group during the fourth quarter worth approximately $7,776,000. Qube Research & Technologies Ltd raised its holdings in Privia Health Group by 93.3% in the second quarter. Qube Research & Technologies Ltd now owns 609,278 shares of the company’s stock valued at $14,013,000 after acquiring an additional 294,101 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in Privia Health Group in the second quarter valued at approximately $6,219,000. Hedge funds and other institutional investors own 94.48% of the company’s stock.

Insider Buying and Selling

In other news, CFO David Mountcastle sold 24,734 shares of Privia Health Group stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $27.50, for a total value of $680,185.00. Following the transaction, the chief financial officer directly owned 186,728 shares of the company’s stock, valued at $5,135,020. The trade was a 11.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew Shawn Morris sold 88,110 shares of Privia Health Group stock in a transaction on Friday, June 26th. The shares were sold at an average price of $25.33, for a total transaction of $2,231,826.30. Following the completion of the transaction, the director directly owned 76,651 shares in the company, valued at $1,941,569.83. The trade was a 53.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 327,886 shares of company stock worth $8,628,256. Insiders own 5.70% of the company’s stock.

Privia Health Group Stock Up 1.1%

PRVA opened at $22.00 on Friday. Privia Health Group, Inc. has a 52 week low of $19.53 and a 52 week high of $28.82. The business’s 50 day moving average is $24.71 and its two-hundred day moving average is $23.29. The firm has a market cap of $2.81 billion, a price-to-earnings ratio of 104.77, a price-to-earnings-growth ratio of 1.77 and a beta of 0.85.

Wall Street Analyst Weigh In

PRVA has been the subject of several analyst reports. Zacks Research upgraded shares of Privia Health Group from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 5th. Barclays reduced their price objective on shares of Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 26th. Citigroup reaffirmed a “buy” rating on shares of Privia Health Group in a research report on Thursday, July 23rd. Weiss Ratings upgraded shares of Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, July 2nd. Finally, Canaccord Genuity Group set a $32.00 target price on Privia Health Group in a report on Friday, August 7th. Eleven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Privia Health Group presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.00.

Privia Health Group Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.